

Oxamidation of Unsaturated O-Alkyl Hydroxamates: Synthesis of the Madangamine Diazatricylic (ABC Rings) Skeleton

Abir Bhattacharjee, Mikhail V. Gerasimov, Sam DeJong, and Duncan J. Wardrop*®

Department of Chemistry, University of Illinois at Chicago, 845 West Taylor Street, Room 4500, Chicago, Illinois 60607-7061, United States

Supporting Information



ABSTRACT: A novel approach to the diazatricyclic madangamine ABC ring system and the synthesis of an advanced, differentially protected intermediate for the synthesis of madangamine D is reported. Central to the success of this approach is the iodine(III)-mediated intramolecular oxamidation of an unsaturated O-methyl hydroxamate, a π -N⁺-type cyclization which proceeds in high yield and with complete regioselectivity to generate the 2-azabicyclo[3.3.1]nonane (morphan) system encompassing rings A and C.

solated from marine sponges of the order *Haplosclerida*, the madangamines are a small family of cytotoxic 3-alkylpiperidine alkaloids (Figure 1).¹ Since the initial discovery of



Figure 1. Members of the madangamine alkaloid family.

madangamine A (1) in 1994 by Andersen,² five other members of this group (B-F, 2-6) have been found.³ The structure of these natural products was initially determined by an extensive combination of spectroscopic techniques, but it was not until 2014 that the absolute configuration of the family was firmly established through enantioselective total synthesis of madangamine D (4).⁴ Although madangamines A (1), D (4), and F (6) display differential cytotoxicity toward a range of tumor cell lines,⁵ investigation of their mode of action or identification of other biological activities has been hampered by their paucity in nature.

Structurally, the madangamines are characterized by a pentacyclic skeleton with variations of the size and degree of unsaturation in macrocyclic rings E and D. With the exception of madangamine F(6), which differs only in being oxidized at the C-4 position, all members of this family share the same diazatricyclic skeleton (rings ABC), encompassing the 2azabicyclo [3.3.1] nonane ring system. Despite sustained interest, only two total syntheses of this group have been reported to date: Amat and Bosch completed the first asymmetric synthesis of (+)-madangamine D (4) in 2014,⁴ while Chida has more recently reported a unified route to madangamines A(1), C (3), and E (5).⁵ In addition to these pioneering accomplishments, several studies directed toward construction of the pendant macrocycles and the tricyclic core have been reported.^{1,6} Routes to the latter system, including the one reported here, can be broadly categorized as following one of the strategies outlined in Figure 2.

The most widely employed approach to the core ABC ring system has been the N-cyclization of cis-perhydroisoquinolines, such as 7 and 8, which encompass rings B and C (A, Figure 2). While Weinreb,⁷ and later Amat and Bosch,^{8a} have employed alkene aminomercuration to establish ring A, ring opening of epoxides of type 8 has been successfully employed by Amat and Bosch to the same end.^{4,8,9} Kibayashi's route to the tricyclic core also features N-1/C-2 (madangamine numbering) bond formation but, in this case, ring A closure was accomplished through generation and reduction of bridgehead iminium ion 9.¹⁰

An alternative approach to ring A formation has been developed by Diaba and Bonjoch, who employed the 6-exo-trig cyclization of 3-aza-6-heptenyl radical 10 to form the C-9/C-11 bond (**B**, Figure 2).¹¹ Routes to the ABC nucleus involving ring C formation been reported by Chida,^{5,12} who used the Nacyliminium cyclization of propargyl silane 11, and Marazano, who has reported the biomimetic condensation of dihydropyridinium ion 12 and the sodium salt of diethylacetonedicarbox-

Received: October 21, 2017 Published: November 28, 2017



Figure 2. Prior and current synthetic approaches to the madangamine diazatricyclic skeleton.

ylate to simultaneously establish the C-2/C-3, C-5/C-11 and C-6/N-7 bonds (C, Figure 2).¹³

Herein, we report a novel approach to the madangamine ABC ring system and the synthesis of an advanced, differentially protected intermediate for the synthesis of madangamine D (4) (**D**, Figure 2). The central transformation of this work involves the cyclization of unsaturated singlet nitrenium ion 13 to generate aziridinium ion 14. Ion pair collapse of this highly reactive intermediate proceeds with complete regioselectivity to simultaneously establish the 2-azabicyclo[3.3.1]nonane madangamine core and introduce functionality at C-3 necessary for later-stage introduction of ring E. Use of this π +N⁺-type alkene oxamidation represents an extension of our ongoing study of nitrenium ions and the application of these reactive intermediates to the synthesis of alkaloid natural products and azacyclic systems, in general.^{14,15}

When planning our route to the madangamine skeleton and madangamine D (4) itself, we envisioned that late-stage, macrocycle installation could be accomplished with most flexibility, viz-à-viz order of D/E ring formation, from fully functionalized, orthogonally protected diamine 16, which encompasses rings ABC (Scheme 1). Disconnection of the N-7/C-8 bond, leading to 17, revealed two challenges: (a) installment of the pivotal quaternary stereocenter at C-9 and (b) construction of the 2-azabicyclo[3.3.1]nonane system itself. Morphan 18 was anticipated to rise from the ring opening of intermediate 19, which would be generated during the iodine(III)-mediated oxamidation of 20.^{15a} One-carbon homologation of *meso* anhydride 21 would then provide ready access to this unsaturated *O*-methyl hydroxamate.

Our route to the madangamine core commenced from imide **22**, prepared in high yield by condensation of *cis*-tetrahydroph-thalic anhydride (**21**) with allylamine (Scheme 2). Treatment of **22** with sodium borohydride in a mixture of *i*-PrOH $-H_2O$ (6:1),¹⁶ and reduction of the resulting γ -hydroxy-*N*-allylamide with LiAlH₄ provided amino alcohol **23** as a single diastereomer in 78% overall yield.¹⁷ Taking advantage of the *p*-tolylsulfonyl

Scheme 1. Retrosynthetic Analysis



Scheme 2. Preparation of Oxamidation Substrate 20



moiety's duality as *N*-protecting group and alcohol activator, **23** was treated with excess (3 equiv) *p*-toluenesulfonyl chloride at low temperature (-30 °C) to generate bis-*N*,*O*-tosylate **24** (74% yield).¹⁸ One-carbon homologation of this material was accomplished by treatment with KCN in DMSO to provide **25** in 83% yield. Nitrile hydrolysis under basic conditions and then carbodiimide-mediated coupling of the resulting carboxylic acid with *O*-methoxylamine gave hydroxamate ester **20** in 90% yield over two steps.

Employing our previously reported conditions for the oxamidation of unsaturated *O*-alkyl hydroxamates, ^{15a} sequential treatment of **20** with trifluoroacetic acid (1.0 equiv) and phenyliodine(III) bis(trifluoroacetate) (PIFA) (1.2 equiv) in CH₂Cl₂, provided **18** in high yield after in situ cleavage of trifluoroacetate ester **26** with methanolic ammonia (Scheme 3). Compound **18** was isolated as a single diastereomer, which arises from regioselective ring opening at C-3;¹⁹ no trace of the 2-azabicyclo[3.2.2]nonan-7-ol arising from distal opening was detected. Importantly, this process is amenable to scale up and has been conducted on multigram scales without decrease in efficiency.

Scheme 3. Generation of 2-Azabicyclo[3.3.1]nonane Ring System



In preparation for generation of the key quaternary stereocenter at C-9, secondary alcohol **18** was oxidized under Swern conditions to provide the corresponding ketone which was condensed with ethylene glycol to provide acetal **27** in excellent overall yield (Scheme 4). Generation of the enolate of





morphan 27 using LiHMDS and addition of ethyl chloroformate provided 28 as a single diastereomer. Now employing anhydrous K_2CO_3 in conjunction with 18-crown- 6^{20} to minimize competitive enolate O-alkylation, 28 underwent exclusive *exo*-face C-alkylation with 11-iodoundecan-1-yl benzyl ether $(29)^{21}$ to provide 30 in near-quantitative yield. As indicated in Scheme 4, the configuration of the quaternary stereocenter was confirmed by a NOESY NMR experiment, which revealed a cross peak between the methylene group of the C-9 ethyl ester and one of the protons of the C-5 *endo* aminomethyl substituent.²²

Rather than cleaving the *N*-methoxyl group of lactam **30**, we now took advantage of this substituent as an *N*-protecting group.²³ Thus, treatment of **30** with excess alane (AlH₃) (2.7 equiv) reduced the lactam and ethyl ester groups but did not cleave the N–O bond, leaving this *N*-center effectively blocked. While, *O*-tosylation of the C-9 hydroxymethyl substituent

proceeded without incident to provide 31, removal of the Nallyl group from this sulfonamide proved to be unexpectedly challenging. In this regard, a number of two-step deallylation methods, involving alkene isomerization and hydrolysis, failed to afford the desired product and led to substrate decomposition. Fortunately, this transformation was accomplished using catalytic quantities of RhCl₃·H₂O (5 mol %) in anhydrous n-propanol at reflux, as reported by Zacuto and Xu.²⁴ These conditions also mediated acetal solvolysis, which may result from the presence of HCl liberated upon the reaction of RhCl₂ with *n*-PrOH. Reacetalization of the C ring ketone, under the conditions employed before, gave 17 in excellent overall yield from compound 31. With the stage now set for closure to form ring B, exposure of 31 to sodium hydride in THF at reflux effected intramolecular N-alkylation to provide 16 in high yield, thereby establishing the ABC madangamine core.

In conclusion, we have developed a general strategy for the preparation of diazatricyclic (ABC) skeleton common to the madangamine alkaloids. The synthesis of advanced intermediate **16**, which is differentially protected and fully functionalized for installation of rings D and E, was accomplished in 17 steps, with an overall yield of 17%. The key transformation in this approach involves formation of the core azabicyclo[3.3.1]-nonane (morphan) framework through the intramolecular oxamidation of an unsaturated *O*-methyl hydroxamate. Extension of the chemistry reported here to the total synthesis of madangamine D and other morphan-based natural products is underway.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.or-glett.7b03283.

Experimental details and characterization data for all reported compounds (PDF)

¹H and ¹³C NMR spectra NMR spectra (PDF)

AUTHOR INFORMATION

Corresponding Author

*E-mail: wardropd@uic.edu.

ORCID [®]

Duncan J. Wardrop: 0000-0002-1234-5626

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank the National Institutes of Health (GM-67176) for financial support of this work. D.J.W. thanks the University of Illinois at Chicago, College of Liberal Arts and Sciences (LAS), for financial support (LAS Award for Faculty of Science).

REFERENCES

(1) For a review of the occurrence, structure and synthesis of the madangamine alkaloids, see: Amat, M.; Pérez, M.; Ballette, R.; Proto, S.; Bosch, J. *Alkaloids Chem. Biol.* **2015**, *74*, 159.

(2) Kong, F.; Andersen, R. J.; Allen, T. M. J. Am. Chem. Soc. 1994, 116, 6007.

(3) (a) Kong, F.; Graziani, E. I.; Andersen, R. J. J. Nat. Prod. **1998**, 61, 267. (b) Oliveira, J. H. H. L.; Nascimento, A. M.; Kossuga, M. H.;

Organic Letters

Cavalcanti, B. C.; Pessoa, C. O.; Moraes, M. O.; Macedo, M. L.; Ferreira, A. G.; Hajdu, E.; Pinheiro, U. S.; Berlinck, R. G. S. J. Nat. Prod. 2007, 70, 538.

(4) Ballette, R.; Pérez, M.; Proto, S.; Amat, M.; Bosch, J. Angew. Chem., Int. Ed. 2014, 53, 6202.

(5) Suto, T.; Yanagita, Y.; Nagashima, Y.; Takikawa, S.; Kurosu, Y.; Matsuo, N.; Sato, T.; Chida, N. J. Am. Chem. Soc. 2017, 139, 2952.
(6) For a review of the synthesis of azabicyclo[3.3.1]nonanes, see:

Bonjoch, J.; Diaba, F.; Bradshaw, B. Synthesis **2011**, 2011, 993.

(7) Matzanke, N.; Gregg, R. J.; Weinreb, S. M.; Parvez, M. J. Org. Chem. 1997, 62, 1920.

(8) (a) Amat, M.; Pérez, M.; Proto, S.; Gatti, T.; Bosch, J. Chem. -Eur. J. 2010, 16, 9438. (b) Proto, S.; Amat, M.; Pérez, M.; Ballette, R.; Romagnoli, F.; Mancinelli, A.; Bosch, J. Org. Lett. 2012, 14, 3916.
(c) Amat, M.; Ballette, R.; Proto, S.; Pérez, M.; Bosch, J. Chem. Commun. 2013, 49, 3149.

(9) For the formation of ring A through a Mitsunobu type aminocyclization, see: Quirante, J.; Paloma, L.; Diaba, F.; Vila, X.; Bonjoch, J. J. Org. Chem. 2008, 73, 768.

(10) (a) Yamazaki, N.; Kusanagi, T.; Kibayashi, C. *Tetrahedron Lett.* 2004, 45, 6509. (b) Yoshimura, Y.; Inoue, J.; Yamazaki, N.; Aoyagi, S.; Kibayashi, C. *Tetrahedron Lett.* 2006, 47, 3489. (c) Yoshimura, Y.; Kusanagi, T.; Kibayashi, C.; Yamazaki, N.; Aoyagi, S. *Heterocycles* 2008, 75, 1329.

(11) (a) Quirante, J.; Escolano, C.; Massot, M.; Bonjoch, J. *Tetrahedron* **1997**, *53*, 1391. (b) Diaba, F.; Pujol-Grau, C.; Martínez-Laporta, A.; Fernández, I.; Bonjoch, J. Org. Lett. **2015**, *17*, 568.

(12) Yanagita, Y.; Suto, T.; Matsuo, N.; Kurosu, Y.; Sato, T.; Chida, N. Org. Lett. 2015, 17, 1946.

(13) Tong, H. M.; Martin, M.-T.; Chiaroni, A.; Bénéchie, M.; Marazano, C. *Org. Lett.* **2005**, *7*, 2437.

(14) For selected reviews of nitrenium ion chemistry, see: (a) Falvey, D. E.. Nitrenium Ions. In *Reactive Intermediate Chemistry*; Moss, R. A., Platz, M., Jones, M., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, 2004; p 593. (b) Kikugawa, Y. *Heterocycles* **2009**, *78*, 571. (c) Wardrop, D. J.; Bowen, E. G.. Synthetic Applications of Nitrenium Ions. In Nitrenes and Nitrenium Ions; Falvey, D. E., Gudmundsdottir, A. D., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, 2013; p 347.

(15) (a) Wardrop, D. J.; Bowen, E. G.; Forslund, R. E.; Sussman, A. D.; Weerasekera, S. L. J. Am. Chem. Soc. 2010, 132, 1188. (b) Bowen, E. G.; Wardrop, D. J. Org. Lett. 2010, 12, 5330. (c) Wardrop, D. J.; Bowen, E. G. Org. Lett. 2011, 13, 2376. (d) Wardrop, D. J.; Yermolina, M. V.; Bowen, E. G. Synthesis 2012, 44, 1199.

(16) Corey, E. J.; Letavic, M. A. J. Am. Chem. Soc. **1995**, 117, 9616. (17) Tanyeli, C.; Odabas, S.; Erdem, M.; Cakir, E.; Keskin, E. Tetrahedron: Asymmetry **2007**, 18, 2349.

(18) Wang, C.; Abboud, K. A.; Phanstiel, O., IV. J. Org. Chem. 2002, 67, 7865.

(19) For the *trans*-diaxial opening of a tricyclic aziridinium ion, see: Sasaki, T.; Eguchi, S.; Toi, N.; Okano, T.; Furukawa, Y. J. Chem. Soc., Perkin Trans. 1 1983, 1, 2529.

(20) Reisch, J.; Iding, M.; von Bassewitz, I. J. Heterocycl. Chem. 1993, 30, 977.

(21) Roland, J. T.; Guan, Z. J. Am. Chem. Soc. 2004, 126, 14328.

(22) For an analogous *exo*-face C-9 alkylation of a morphan system, see: ref 11b.

(23) For an example of this strategy, see: Shirokane, K.; Wada, T.; Yoritate, M.; Minamikawa, R.; Takayama, N.; Sato, T.; Chida, N. *Angew. Chem., Int. Ed.* **2014**, *53*, *512*.

(24) Zacuto, M. J.; Xu, F. J. Org. Chem. 2007, 72, 6298.